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Christine Xia1 and Ajay Gautam2, ajay.gautam@astrazeneca.com
The pharmaceutical industry has responded to the declining research and development (R&D)
productivity over the past decade by decreasing its cost base and outsourcing parts of drug research, with
China increasingly being the preferred destination for such outsourced work. For this Focus article, we
collected and analyzed data for 66 China-based nonclinical contract research organizations (CROs);
approximately 60% of the companies were localized in the Yangtze River Delta cluster and another 20%
within the Beijing cluster. Almost 25% of the companies offered services in discovery biology, the single
largest service offering in the data set, with another 20% offering preclinical research (toxicology,
pharmacology, and animal models) and approximately 15% offering pharmaceutical development. The
biologics and pharmaceutical development services represent key future growth areas, with CROs
showing an increasing appetite for risk-sharing partnerships.
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Gautam and Yang recently published a frame-
work for biomedical innovation in the emerging
markets [1], with China rapidly transitioning to-
wards a future innovator. A key element of such
innovation ecosystems is the presence and
growth of a robust CRO industry. Unlike its
competitors in India, the Chinese CRO industry
has successfully transitioned from the early years
of niche outsourcing to achieving a large scale
and breadth of service offerings, thereby con-
tributing significantly towards innovation output
in China.
The major driver of the growth of the Chinese
CRO industry has been the outsourcing needs of
biopharmaceutical companies, with a significant
portion of research being outsourced each year
by the global innovator companies as part of
R&D restructuring and cost-cutting initiatives [2].794 www.drugdiscoverytoday.com
1359-6446/ 2015 The Authors. PAdditionally, the Chinese Government identified
biotechnology as one of the several strategic
industries, with Government funding of ap-
proximately US$2 billion earmarked for discov-
ering new drugs in the 12th 5-year plan for
2011–2015. In addition, the Government also
earmarked large investments towards life sci-
ence clusters, further supporting the growth and
colocalization of CROs within such clusters. Fi-
nally, strong profitability and balance sheets are
being utilized by large CROs for acquisitions,
leading to consolidation within the industry.
We collected data for 66 China-based non-
clinical CROs across various outsourcing seg-
ments, including chemistry, biology, drug
metabolism, toxicology, and genomics (see the
Supplementary material online for data and
methodology). The data set also included key
publicly available parameters, such as serviceublished by Elsevier Ltd. This is an open access article under the CC BYofferings, and size and location of the orga-
nizations. On the basis of the data, we classified
the CROs as either ‘Integrated’, representing
CROs that offer multiple service segments, or
‘Niche’, representing only one to two service
offerings. Furthermore, the clusters were also
classified as ‘Established’ or ‘Emerging’, based on
the number of CROs in each cluster within the
database, with Established clusters covering at
least 20% of the CROs in the list (the median
value of the CRO distribution in the clusters was
17.5%; Fig. 1b). Finally, we categorized our CRO
data set into seven service offerings: (i) Discovery
chemistry: synthetic, chiral, and analytical
chemistry, and peptide services; (ii) Discovery
biology: reagent service (DNA, RNA, protein, or
antibody products; gene or virus construct),
molecular biology, cell line generations, in vitro
and/or vivo pharmacology, and in vitro drug-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
http://dx.doi.org/10.1016/j.drudis.2015.02.007
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FIGURE 1
(a) Key contract research organization (CRO) clusters in China. The Yangtze River Delta on the eastern coast includes Shanghai, Suzhou, Nanjing, and Hangzhou.
The Beijing cluster in the north includes Beijing and Tianjin. The Central cluster in central-western part of China includes Chengdu, Wuhan, Chongqing, and
Kunming. The Pearl River Delta cluster includes Guangzhou and Shenzhen in the southeast of China. (b) Data set analysis for the localization of CROs across the key
China clusters. The Yangtze River Delta cluster comprises almost two-thirds of the CROs in the data set, followed by the Beijing Cluster representing 20% and the
Central Cluster approximately 15%. The Pearl River Delta cluster has a low representation of CROs. B
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vices; (iii) Genomics: genomics, proteomics,
bioinformatics, biochips, and molecular diag-
nosis; (iv) Preclinical: good laboratory practice
(GLP) and nonGLP toxicology and safety phar-
macology, and animal model services, including
transgenic and disease models (rodents, dogs,
and nonhuman primates); (v) Pharmaceutical
development (Pharm. dev.): process R&D, pre-
formulation, formulation, and active pharma-
ceutical ingredient (API) and/or intermediates
manufacturing; (vi) Biologics: monoclonal anti-
body (mAb) discovery, chemistry, manufacturing
and control (CMC) and biologics manufacturing;
and (vii) Integrated: those CROs offering three or
more of the above services.
The CRO landscape in China
The initial CROs in China were established during
the 1990s primarily in the Beijing area, with SBSGenetech, JOINN Labs, and SinoGenoMax pro-
viding small-scale research services, such as DNA
synthesis, drug safety assessment, and genome
sequencing, to local customers. By the early 2000s,
most big pharma companies had outsourcing
activities in China on various scales. Eli Lilly was
one of the first companies to outsource discovery
projects, facilitating the establishment of Shang-
hai ChemExplorer in 2002, which subsequently
became part of ShangPharma. Pfizer and Merck
were also pioneer users of Chinese CROs on a
large scale: in 2005 and 2006, they were the
largest customers of WuXi AppTec (formerly Wuxi
PharmaTech), accounting for 17.4% each in 2005
and 15.4% and 13.7% in 2006, respectively, of the
net revenues of WuXi (data from WuXi AppTec
public filings). Over the past few years, several
small and mid-size biotechs have also joined big
pharma companies in outsourcing parts of their
drug discovery processes to China.To understand the localization of the CROs
across various clusters in China and the evolution
of their service offerings, we classified the CRO
data set using a 2  2 matrix for the cluster
maturity and level of service offerings. Not sur-
prisingly, CROs are concentrated in the major
life-science clusters of China. The Yangtze River
Delta region, which includes Shanghai, Suzhou,
Hangzhou, and Nanjing, contains 61% of the
CROs in our data set, with another 20% located in
the Beijing cluster (Fig. 1). Both of these have
more than the median value of the CRO distri-
bution and are classified as the ‘Established
clusters’. The Central cluster comprising the
Wuhan–Chongqing–Chengdu triangle has an-
other 15% of the CROs, whereas the remainder
are located in the Pearl River Delta region. Both
of these regions have less than the median value
of the CRO distribution and are classified as
‘Emerging clusters’.www.drugdiscoverytoday.com 795
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FIGURE 2
A snapshot of contract research organization (CRO) localization and service offerings in Chinese CRO clusters. Data on the level of service offerings and the cluster
maturity were used to assign representative CROs in a 2  2 matrix. The circles are color coded for the cluster location and the size of the circle represents the full-
time equivalent (FTE) number for the organization. Select representative companies are shown.
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located in the Established clusters, whereas
Niche CROs with specialty services have a higher
presence and growth in the Emerging clusters
(Fig. 2). However, as Integrated CROs face their
own cost pressures in Established clusters, these
companies are creating satellite sites for Niche
services in the Emerging clusters to gain scale,
realize cost advantages, and access local pro-
vincial incentives. For example, Wuxi AppTec and
Chempartner created chemistry sites in the
Emerging clusters of Wuhan and Chengdu,
respectively. Meanwhile, Niche companies are9% 
26% 
10% 21% 
9% 
14% 
11% 
FIGURE 3
Distribution of services offered by contract research o
services in three areas: discovery biology (26%), preclin
There is also an increasing representation of Integrat
industry.
796 www.drugdiscoverytoday.comalso establishing new services, such as animal
models or toxicology, in the Emerging clusters to
both leverage the local environment as well as to
avoid direct competition with the Integrated
companies in the Established clusters. Specific
cities have built expertise in differentiated seg-
ments, such as Shenzhen for bioinformatics,
Suzhou for medical devices, and Nanjing for
animal models.
With respect to the service offerings and or-
ganizational size, most CROs fall in the Niche
category and are of a small size [10–500 full-
time equivalents (FTEs)] and focused serviceDiscov. Chem 
Discov. Bio 
Genomics 
Preclinical 
Biologics 
Pharm. Dev. 
Integrated 
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rganizations (CROs) in China. Most CROs offer
ical (21%), and pharmaceutical development (14%).
ed CROs (11%) driven by consolidation in therange (one to two services). The top three
service areas are discovery biology (approxi-
mately 25%), preclinical (approximately 20%),
and pharmaceutical development (approxi-
mately 15%) (Fig. 3).
Finally, we found that Integrated and Niche
CROs are adopting different business strategies
and partnership models with their biopharma-
ceutical partners. Integrated CROs provide the
partners with creative structures, such as risk
sharing, with a one-stop services platform; for
example, the joint venture between Wuxi App-
Tec and AZ/MedImmune for the development,
manufacturing, and commercialization of novel
biologics, or the ShangPharma partnership with
Jiangsu Hengrui Medicine for the development
of mAbs. By contrast, Niche CROs prefer a tra-
ditional fee-for-service model for their specialty
offering, although they are also attempting to
establish strategic drug discovery partnerships
to support novel product development. Exam-
ples include the 3D BioOptima partnership with
BeiGene to provide a dedicated preclinical DMPK
service to support new anticancer drug candi-
dates, including the second-generation BRAF
inhibitor BGB-283, which BeiGene outlicensed to
Merck-Serono. There are also increasing colla-
borations among Niche CROs to help provide
broader offerings for customers. One such ex-
ample is the strategic partnership between Viva
Biotech, with strengths in structure-based drug
discovery, and HitGen, a hit identification and
Drug Discovery Today  Volume 20, Number 7  July 2015 PERSPECTIVE
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Elead generation CRO, to provide customers with
full range of drug discovery services.
Drivers impacting industry dynamics
We found several drivers that are impacting the
CRO landscape in China.
Drug discovery outsourcing needs
Discovery outsourcing has been used by phar-
maceutical and biotech companies to improve
R&D productivity, manage costs, and create
operational flexibilities [2,3]. The increased
complexity of biological targets, portfolio prior-
itization, and budget constraints also result in
pharmaceutical and biotech companies out-
sourcing certain discovery activities on either
noncore or lower priority assets. These out-
sourcing activities are spread across the dis-
covery continuum, from chemical synthesis to
target identification and validation to biological
testing, for example. Chinese CROs have also
built new technology platforms for genomics
and proteomics research, high-throughput
screening platforms, and mature assays, such as
G-protein-coupled receptor (GPCR) panel
screening, enzymatic, and binding assays to
validate complex and diverse disease targets. At
the preclinical stage, transgenic and disease
animal models have been well developed for
target validation, efficacy, and safety studies,
thereby providing clients with an entire service
platform. China has been a preferred location for
life-science outsourcing primarily because of the
end-to-end technology capabilities that have
been built over the years.
Small to mid-size biotechs in the USA and
Europe as well as virtual companies [4] with
minimal investment in in-house research labs are
another reason for increased discovery out-
sourcing, much of which is flowing to China.
These companies typically have a business
model to develop compounds from discovery
and preclinical stages through proof-of-concept
(PoC) before licensing out to big pharma com-
panies. CROs serve as an ideal, cost-effective
partner for these companies until a drug can-
didate reaches the clinical stage. The Pharmasset
hepatitis C compound sofosbuvir, later acquired
by Gilead and recently launched as SolvadiTM,
was synthesized at WuXi AppTec and is a good
example of such an outsourcing strategy by
small or virtual biotech companies. Agios and
Epizyme are good examples of biotechs that
have built innovative outsourcing alliances in
China to facilitate their internal R&D. Even certain
big pharma companies have therapy area units
that are virtual in nature and perform most of
their research externally through a network ofCROs; these could also be an additional source of
growth for Chinese CROs.
Government policy and initiatives
Many of the CROs in our data set are based in the
major life-sciences clusters in China and are
colocalized with big pharma discovery units and
local innovative biotech companies; thus, they
are able to work in close proximity with clients.
These CROs can further tap into the cluster
strengths (the infrastructure, incubators, and
public R&D facilities within the science parks on
the one hand, and policies and incentives, such
as subsidies, permits, import channels, talent
pool, and financing, on the other hand). One
such example is the bioBay Park located in
Suzhou city that was built in 2006. Today, bioBay
has more than 360 high-tech innovative com-
panies with an estimated US$800 million regis-
tered capital in its 1,000,000 m2 campus and
provides comprehensive services to the hosted
companies (data from bioBay presentations).
CRO industry is one of its five sectors, with
companies mostly on a small or medium scale,
covering a broad spectrum of services, from
chemistry synthesis, reagent provisioning, gene
synthesis and/or sequencing, and API and bio-
logics manufacturing (see Supplementary ma-
terial online). The representative CRO or
subsidiaries include the bioinformatics player
Genewiz, the antibody subsidiary of Wuxi App-
Tec, Abgent (although this facility recently
moved from bioBay to a different part of Suz-
hou), and Innovent Biologics. Several such high-
tech parks across China are facilitating the
growth of the Chinese CRO industry.
Consolidation
Mergers and acquisitions is another driver that is
transforming the Chinese CRO industry. The
large, Integrated CROs driven by the strong
profitability and access to financing are seeking
to quickly enter new business areas to build a
one-stop platform. Wuxi AppTec is a prime ex-
ample of such a strategy and its stated vision is
to ‘create an open access capability and tech-
nology platform’ that can facilitate drug dis-
covery and development, almost as an
equivalent of Amazon for drug R&D. In 2011,
Wuxi AppTec completed a series of transactions
such as the acquisition of Abgent to expand its
coverage of biological reagents and services, and
closed deals with MedKey Med-Tech Develop-
ment and Jiecheng Med-Tech Development to
establish clinical and regulatory services. Simi-
larly, Pharmaron tapped into preclinical GLP
toxicology services via acquisition of Bridge
Laboratories China in 2010. ShangPharmaacquired the in vivo facility of Charles River in
Shanghai through its main Chinese subsidiary,
Shanghai ChemPartner, in 2011. These consoli-
dations made Wuxi AppTec, Pharmaron, and
ShangPharma the top tier one-stop Integrated
service suppliers in China. Additionally, multi-
national CROs acquiring local China CROs to
enter the market is also on the rise, such as the
acquisition of BioDuro by PPD.
Future growth opportunities
We also see several growth opportunities for the
CRO industry in China.
Specialty offerings
One of the key areas of robust growth is the Niche
services segment, which targets the growing
biotech sector in the USA and Europe apart from
big pharma clients. CROs, such as HD Biosciences,
serve Pfizer, Lilly, and Janssen in target identifi-
cation, hit generation, and optimization studies,
as well as targeted animal model projects. BGI,
WuXi Genome Center, and Genewiz are key Chi-
nese players in next-generation sequencing,
which is one of the priority technology develop-
ment areas highlighted in the 12th 5-year plan of
China. In 2011, Merck and BGI established a
strategic collaboration focused on biomarkers
and genomic technologies. In the peptide area,
the Chinese Peptide Company (CPC) offers ser-
vices to Pfizer, AstraZeneca, and other companies
based around custom synthetic peptide or API
manufacturing. Kunming Biomedicine Interna-
tional (KBI), a CRO based in Kunming city, has
created a Niche service focused on nonhuman
primates studies specializing in GLP in vivo
pharmacology, pharmacokinetics/pharmacody-
namics (PK/PD), DMPK and/or bioanalysis, and
pharmacological toxicology services. Another
such example of a Niche CRO in an Emerging
cluster is CarysBio (discussed in more detail in the
Supplementary material online).
Innovative knowledge and new technology
partnering with academia and universities also
present future growth opportunities. In 2013,
HDB, the Marshall Institute for Interdisciplinary
Research (MIIR), and the Joan C. Edwards School of
Medicine of Marshall University agreed to code-
velop potential anticancer drugs. Another recent
example was the partnership between Crown
Biosciences and Shanghai Institute of Materia
Medica (SIMM) to develop a world-leading pre-
clinical rodent center with a large annotated
patient-derived tumor graft (PDX) model and
translational oncology platform. We expect such
partnerships to continue growing in the future,
helping Niche CROs access novel technology to
supplement their service offerings.www.drugdiscoverytoday.com 797
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As biologics become a larger portion of global
biopharma portfolios, Chinese CROs are building
capabilities in cell line development, process
development, and manufacturing for therapeu-
tic proteins and mAbs to take advantage of this
dynamic. Innovent Biologics represents an im-
portant trend in the Chinese biologics CRO
space. Innovent was established in 2011, with
investments from Fidelity Biosciences, Innovent
Biologics, and Lilly Asia Ventures. It provides
products and manufacturing services in anti-
body, protein, and cell lines. In 2012, WuXi
AppTec opened the first cGMP biologics facility
in Wuxi city in China to supply mAb drug sub-
stances for customers. The same year, WuXi
AppTec and MedImmune, the biologics subsid-
iary of AstraZeneca, formed a joint venture (JV)
to develop novel biologic MEDI5117 for the
Chinese market (discussed in further detail in the
Supplementary material online). The recent US
Food and Drug Administration (FDA) IND ap-
proval of ibalizumab (TMB-355) developed by
TaiMed and manufactured at Wuxi AppTec is a
major boost to this sector.
Pharmaceutical development
Pharmaceutical development outsourcing is
driven by an increasing customer need, im-
proved quality standards, and local regulatory
requirements within China. This is an area where
India has historically led the way, but China is
catching up fast. In recent years, local CROs have
been aggressively enhancing their capacities
and capabilities in this new area, and the facil-
ities of several CROs have been qualified by
regulatory authorities, such as the US FDA, Eu-
ropean Medicines Agency (EMA), and China
Food and Drug Administration (CFDA). For in-
stance, Wuxi AppTec is building its phase one
Changzhou site to double its current
manufacturing capacity. Pharmaron is also
establishing a cGMP manufacturing facility in
Tianjin. CPC completed its phase one
manufacturing facility expansion for peptide APIs
during early 2014. Other facilities of domestic
pharmaceutical companies that also provide
custom services, but not listed in our CRO data set,
such as Portron, Yangtze River Pharmaceutical
Group, and Huahai Pharmaceutical, among
others, also passed either US FDA or EMA audits.
The capabilities of CROs are further
strengthened by the large number of Chinese
returnees who bring with them the knowledge
and quality management systems from their
experience working in the USA or Europe, and
are often instrumental in founding CROs in798 www.drugdiscoverytoday.comChina. Several areas, such as asymmetric syn-
thesis, high potency and/or cytotoxics, low
temperature reactions, and catalytic hydroge-
nations are already well established and newer
technologies, such as flow chemistry and
microreactor on a kilogram scale, are also being
developing by many CROs. There is now an
increased outsourcing of preformulation, for-
mulation, and API manufacturing to China con-
current with the improved technical capabilities
and quality as well as for local regulatory
requirements. One such example of a CRO
spearheading capabilities in this area is Asym-
chem (discussed in more detail in Supplemen-
tary material online).
Concluding remarks
R&D productivity challenges will continue to
drive increased outsourcing and we see China as
the leading destination for such work. The CRO
industry has been a vital contributor to the
innovation ecosystems of Established clusters,
such as Shanghai and Beijing, and we envision
that the Niche companies will continue to grow
and provide a similar stimulus to the innovation
landscape of the Emerging clusters, such as
Wuhan and Chengdu. In parallel, there will be a
continued consolidation of the industry to
achieve a bigger scale and breadth of services
over the next 3–5 years. Wuxi AppTec partnering
with PRA International and the acquisition of
Frontage by TigerMed are examples of how large
CROs are building full capability R&D service
platforms. The healthcare reforms underway in
China will also provide the large Integrated
companies with an opportunity to leverage their
cash flows and balance sheets to diversify further
into adjacent services, such as medical device
testing, hospitals, and clinical services, as well as
to explore other opportunities in the broader
healthcare space. Niche CROs could explore
moving higher up in the value chain by
leveraging their differentiated expertise. Chinese
CROs will also be more risk tolerant, whether it is in
the form of risk-sharing partnering models with
innovative companies, or direct investments into
new technologies or platforms. Finally, China will
continue to strengthen its leads within the CRO
industry compared with other markets, such as
India, because of the capabilities built in biology,
toxicology, and platform technologies.
There are still challenges that the industry will
have to navigate over the coming years. The
primary one is the increasing operating costs,
especially in the Established clusters, such as
Shanghai and Beijing, making the Chinese CRO
services less competitive compared with its USAor European counterparts. Already, the wages for
senior management and high-income groups in
these cities are starting to mirror those of western
markets and the lower income groups are likely to
catch up over the coming years. Another area is
the continued investment needs and appetite of
investors for new technology platforms to keep
the local industry competitive. China has built
strong capabilities in biology, next-generation
sequencing, genomics, toxicology, and animal
models, and will need to continue investing in
these and new technology areas to keep its
competitive advantage. Additionally, as the Inte-
grated CROs scale up, they need to bring in the
processes and systems to extract operational
efficiencies. Many of these players have grown up
too quickly, and suffer from the ‘large company in
start-up mode’ syndrome; therefore, they will
need to implement rigorous systems to manage
future growth. Finally, quality concerns and
compliance are areas of concern and focus, and
the Chinese CRO companies will need to be
vigilant in these critical areas to maintain the
pharmaceutical and biotech partner confidence
in their service offerings.
Disclosure
C.X. and A.G. are current AstraZeneca employees,
and AstraZeneca uses the services of some of the
CROs mentioned in this article.
Appendix A. Supplementary data
Supplementary material related to this article
can be found, in the online version, at http://dx.
doi.org/10.1016/j.drudis.2015.02.007.
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